Consensus Guidelines For The Management And Treatment Of Neuroendocrine Tumors.
P. Kunz, D. Reidy-Lagunes, L. Anthony, E. Bertino, Kari Brendtro, J. Chan, H. Chen, R. Jensen, M. Kim, D. Klimstra, M. Kulke, E. Liu, D. Metz, A. Phan, R. Sippel, J. Strosberg, J. Yao
Published 2013 · Medicine
Download PDFAnalyze on Scholarcy
Neuroendocrine tumors are a heterogeneous group of tumors originating in various anatomic locations. The management of this disease poses a significant challenge because of the heterogeneous clinical presentations and varying degrees of aggressiveness. The recent completion of several phase 3 trials, including those evaluating octreotide, sunitinib, and everolimus, demonstrate that rigorous evaluation of novel agents in this disease is possible and can lead to practice-changing outcomes. Nevertheless, there are many aspects to the treatment of neuroendocrine tumors that remain unclear and controversial. The North American Neuroendocrine Tumor Society published a set of consensus guidelines in 2010, which provided an overview for the treatment of patients with these malignancies. Here, we present a set of consensus tables intended to complement these guidelines and serve as a quick, accessible reference for the practicing physician.
This paper references
The North American Neuroendocrine Tumor Society Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Pheochromocytoma, Paraganglioma, and Medullary Thyroid Cancer
H. Chen (2010)
Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.
D. Kwekkeboom (2008)
Hepatic neuroendocrine metastases: does intervention alter outcomes?
R. Chamberlain (2000)
The Pathologic Classification of Neuroendocrine Tumors: A Review of Nomenclature, Grading, and Staging Systems
D. Klimstra (2010)
NANETS treatment guidelines: well-differentiated neuroendocrine tumors of the stomach and pancreas.
M. Kulke (2010)
The NANETS Consensus Guidelines for the Diagnosis and Management of Gastrointestinal Neuroendocrine Tumors (NETs): Well-Differentiated NETs of the Distal Colon and Rectum
L. Anthony (2010)
Neuroendocrine Hepatic Metastases: Does Aggressive Management Improve Survival?
J. Touzios (2005)
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
M. Pavel (2011)
Aggressive Surgery Improves Long-term Survival in Neuroendocrine Pancreatic Tumors: An Institutional Experience
P. Schurr (2007)
Update on the management of neuroendocrine hepatic metastases.
D. Madoff (2006)
The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Jejunum, Ileum, Appendix, and Cecum
J. Boudreaux (2010)
Sunitinib malate for the treatment of pancreatic neuroendocrine tumors.
E. Raymond (2011)
Placebo-controlled, double-blind, prospective, randomized study of the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: A report from the PROMID study group.
R. Arnold (2009)
NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors: Well-Differentiated Neuroendocrine Tumors of the Thorax (Includes Lung and Thymus)
A. Phan (2010)
First‐line chemotherapy with capecitabine and temozolomide in patients with metastatic pancreatic endocrine carcinomas
J. Strosberg (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors
J. A. Stockman (2012)
Pathology Reporting of Neuroendocrine Tumors: Application of the Delphic Consensus Process to the Development of a Minimum Pathology Data Set
D. Klimstra (2010)
Surgical treatment of neuroendocrine metastases to the liver: a plea for resection to increase survival.
J. Sarmiento (2003)
Treatment of advanced disease in patients with well-differentiated neuroendocrine tumors
D. Reidy (2009)
The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas.
J. Strosberg (2010)
Chromogranin A and neuron-specific enolase as prognostic markers in patients with advanced pNET treated with everolimus.
J. Yao (2011)
This paper is referenced by
Octreotide s.c. depot provides sustained octreotide bioavailability and similar IGF-1 suppression to octreotide LAR in healthy volunteers
Fredrik Tiberg (2015)
Modern Surgical Treatment and Genomic Profiling of Pancreatic Neuroendocrine Neoplasms - from the Operating Theater to the Gene Lab
Sven-Petter Haugvik (2016)
Gastrointestinal neuroendocrine tumors: slow but steady progress.
Arvind Dasari (2014)
Gastrointestinal cancers in inflammatory bowel disease: An update with emphasis on imaging findings.
M. Barral (2016)
Advances in the diagnosis and treatment of gastric neuroendocrine neoplasms.
Huangying Tan (2016)
Prospective Evaluation of Results of Reoperation ison Syndrome in Zollinger-Ell
Jeffrey A. Norton (2018)
Treatment Outcomes in Patients with Metastatic Neuroendocrine Tumors: a Retrospective Analysis of a Community Oncology Database
Maxine D. Fisher (2018)
Radionuclide imaging and therapy in patients with neuroendocrine tumors
Olga D. Baranova (2018)
Management of asymptomatic, well-differentiated PNETs: results of the Delphi consensus process of the Americas Hepato-Pancreato-Biliary Association.
J. Mansour (2019)
Pancreatic neuroendocrine neoplasms: The latest surgical and medical treatment strategies based on the current World Health Organization classification.
Hirotaka Ishida (2019)
Incidence trend and conditional survival estimates of gastroenteropancreatic neuroendocrine tumors: A large population‐based study
Q. Zhong (2018)
Incidentalomas of the Pancreas
John C Mcauliffe (2016)
Consensus-Derived Quality Performance Indicators for Neuroendocrine Tumour Care
B. Woodhouse (2019)
Systemic Therapies for Metastatic Pancreatic Neuroendocrine Tumors
Haley Hauser (2019)
Tumors of the Gastrointestinal System Including the Pancreas
M. Taggart (2020)
Non-functional neuroendocrine tumors of the pancreas: Advances in diagnosis and management.
J. Cloyd (2015)
Risk-reduction surgery in pediatric surgical oncology: A perspective.
J. Sandoval (2016)
Grade Increases in Gastroenteropancreatic Neuroendocrine Tumor Metastases Compared to the Primary Tumor
F. Grillo (2015)
Gastroenteropancreatic neuroendocrine tumors: recommendations of Turkish multidisciplinary neuroendocrine tumor study group on diagnosis, treatment and follow-up
Ş. Yalçın (2017)
Pancreatic Neuroendocrine Neoplasms: Basic Biology, Current Treatment Strategies and Prospects for the Future
A. Ohmoto (2017)
Neuroendokrine Tumoren des Pankreas
Kim Christin Honselmann (2018)
Pancreatic neuroendocrine tumor with splenic vein tumor thrombus: A case report
Rodrigo Rodríguez Rodríguez (2014)
[Tissue heterogeneity contributes to suboptimal precision of WHO 2010 scoring criteria for Ki67 labeling index in a subset of neuroendocrine neoplasms of the pancreas].
Łukasz Liszka (2016)
Novel biomarkers of cardiovascular disease: Applications in clinical practice
M. Lyngbakken (2019)
Metachronous liver metastases after long-term follow-up of endoscopic resection for rectal neuroendocrine neoplasms: a report of three cases
Yuma Hane (2020)
Primary small cell neuroendocrine carcinoma of the anterior mediastinum presenting with trepopnea
Mohamed Iliyas (2018)
The Novel Cyclin-Dependent Kinase 4/6 Inhibitor Ribociclib (LEE011) Alone and in Dual-Targeting Approaches Demonstrates Antitumoral Efficacy in Neuroendocrine Tumors in vitro
E. T. Aristizabal Prada (2017)
The Surgical Management of Small Bowel Neuroendocrine Tumors: Consensus Guidelines of the North American Neuroendocrine Tumor Society
J. Howe (2017)
Gastroenteropancreatic—origin neuroendocrine carcinomas
Yong Gyun Won (2017)
Recent advances in the management of endocrine malignancies associated with hereditary hyperparathyroidism syndromes
Yulong Li (2017)
Outcome after pancreatectomy for neuroendocrine neoplams according to the WHO 2017 grading system: A retrospective multicentric analysis of 138 consecutive patients.
Regis Souche (2019)
Surgical Management of Pancreatic Neuroendocrine Tumors.
Jason B Liu (2016)See more